UBQLNL

Model summary

A soluble scaffold that uses an N-terminal ubiquitin-like module to dock onto the proteasome and a larger ubiquilin scaffold to capture client proteins, thereby coordinating proteostasis in the cytosol and nucleoplasm. By assembling degradation- and autophagy-coupled complexes, it promotes efficient turnover of damaged or regulatory proteins and attenuates excessive antiviral signaling downstream of cytoplasmic pattern recognition pathways.

Predicted Gene Ontology terms

1. 01

   I begin with the InterPro architecture.

   The N-terminus carries IPR029071 (Ubiquitin-like domain superfamily, residues 3–101), and within this superfamily envelope sits a canonical IPR000626 Ubiquitin-like domain (residues 31–105). This β-grasp fold mimics ubiquitin and is a hallmark of the ubiquilin family, which is explicitly captured by IPR015496 (Ubiquilin family, residues 30–474) spanning nearly the full length of the polypeptide. The ordered layout—an N-terminal ubiquitin-like (UBL) module embedded in a larger ubiquilin scaffold—creates a bifunctional platform: the UBL domain recruits the 26S proteasome, while distal regions of the ubiquilin scaffold mediate cargo recognition and additional protein contacts. This architecture causes multivalent protein binding as the primary molecular function, aligning with GO:0005515 protein binding.

2. 02

   From this molecular function, I infer the biological role.

   UBL-driven proteasome docking and ubiquilin-family scaffolding together enable selective proteostasis—capturing and delivering ubiquitylated substrates to the proteasome and coordinating with autophagy pathways. Such proteostasis hubs frequently intersect with innate immune signaling. By sequestering or routing signaling adaptors and pattern-recognition pathway components, this scaffold can attenuate cytoplasmic DNA-sensing outputs. That logic supports the process formalized as GO:0039532 negative regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway: the protein’s binding-driven assembly and trafficking activities dampen antiviral signaling cascades.

3. 03

   Cellular location follows from the same architecture and cargo flow.

   UBL-mediated proteasome engagement and autophagy coupling typically occur in the soluble phase of the cell, consistent with GO:0005829 cytosol. Many ubiquilin-family proteins shuttle into the nucleus to manage nuclear proteostasis and transcription-coupled turnover, supporting GO:0005654 nucleoplasm. The absence of transmembrane features and the presence of soluble interaction modules reinforce a cytosolic/nucleoplasmic distribution.

4. 04

   Mechanistically, I hypothesize that the N-terminal UBL domain docks the 26S proteasome, while the broader ubiquilin scaffold binds client proteins and autophagy machinery.

   This dual engagement allows the protein to triage substrates between degradation routes and to suppress excessive innate immune signaling by routing or sequestering pathway components. Likely interaction partners include the proteasome regulatory particle, ubiquitin/ubiquitin-like shuttle factors, and autophagy receptors; together they form a dynamic complex that maintains protein homeostasis and restrains antiviral signaling intensity.